Petrilli, Alejandra M <br/><br/>
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.  [electronic resource] 

 -  Oncotarget  May 2017 
 - 31666-31681 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.15912  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Cyclin D1--metabolism<br/>Cyclin-Dependent Kinase Inhibitor p27--metabolism<br/>Focal Adhesion Protein-Tyrosine Kinases--metabolism<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Imidazoles--pharmacology<br/>MAP Kinase Signaling System--drug effects<br/>Neurilemmoma--genetics<br/>Neurofibromin 2--deficiency<br/>Paxillin--metabolism<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Pyridazines--pharmacology<br/>Receptors, Platelet-Derived Growth Factor--metabolism<br/>STAT3 Transcription Factor--metabolism<br/>Schwann Cells--drug effects<br/>Signal Transduction--drug effects<br/>src-Family Kinases--metabolism